Besremi (Ropeginterferon Alfa-2b) for Myeloproliferative Neoplasms

Overview
Besremi is approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of polycythemia vera (PV), a type of myeloproliferative neoplasm characterized by the overproduction of red blood cells. Besremi is also known by its drug name, ropeginterferon alfa-2b.

Besremi is a form of interferon alfa, a drug class that works by enhancing the immune system’s ability to control the abnormal production of blood cells. In people with PV, Besremi helps to reduce the excess red blood cells, helping to manage blood counts and reduce the risk of complications associated with the disease.

How do I take it?
Prescribing information states that Besremi is administered as a subcutaneous (under-the-skin) injection. The recommended starting dose is one injection every two weeks, which can be adjusted based on the recipient’s response and blood test results. Dosing may be increased over time until blood cell levels are stabilized, with a maximum dosing frequency of every two weeks. Besremi should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Besremi include flu-like symptoms, joint pain, fatigue, itching, sore throat, and musculoskeletal pain.

Rare but serious side effects may include severe psychiatric disorders (such as depression or suicidal thoughts), endocrine toxicity (disorders in hormone-producing glands), autoimmune conditions, cardiovascular issues (such as heart problems), low blood cell counts, hypersensitivity reactions, pancreatitis, colitis (inflammation of the colon), pulmonary (lung) toxicity, eye disorders, high blood lipid levels, liver damage, kidney impairment, dental issues, and skin reactions. People taking this medication should avoid driving or using machinery if they experience dizziness, drowsiness, or confusion.

For more information about this treatment, visit:

Label: Besremi- Ropeginterferon Alfa-2B Injection — DailyMed